Cytokinetics

Cytokinetics

Develops drugs for muscle function disorders

About Cytokinetics

Simplify's Rating
Why Cytokinetics is rated
C+
Rated D+ on Competitive Edge
Rated B on Growth Potential
Rated B on Differentiation

Industries

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

1998

Overview

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, targeting conditions like heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company is distinct from competitors due to its specialized focus on muscle-related therapies and a strong pipeline of drugs currently in clinical trials. Cytokinetics aims to meet the unmet medical needs of patients by bringing effective treatments to market.

Simplify Jobs

Simplify's Take

What believers are saying

  • Cytokinetics is readying for potential regulatory approvals of aficamten in 2025.
  • The company has strategic partnerships, like with Sanofi, for global market expansion.
  • Cytokinetics' focus on innovative muscle biology positions it well in personalized medicine.

What critics are saying

  • Increased competition from companies like Imbria Pharmaceuticals could impact market share.
  • Reliance on partnerships, such as with Sanofi, poses risks if expectations aren't met.
  • Heavy investment in clinical trials could strain finances if approvals aren't achieved.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and aficamten.
  • Cytokinetics leverages over 25 years of pioneering muscle biology research.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1660.5M

Above

Industry Average

Funded Over

4 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Health Insurance

Paid Vacation

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↓ -1%

2 year growth

↓ -1%
Stock Titan
May 15th, 2025
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

Cytokinetics (NASDAQ: CYTK) announced its second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) scheduled for May 30th, 2025, at the Mission Bay Conference Center in San Francisco.

GlobeNewswire
May 8th, 2025
Cytokinetics Announces Four Upcoming Presentations At The European Society Of Cardiology Heart Failure 2025 Congress

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025.Late Breaking Science PresentationsTitle: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild SymptomsPresenter: Iacopo Olivotto, M.D., Professor of Cardiology at the University of Florence, Head of Cardiology at Meyer Children's Hospital, Florence, ItalyDate: May 17, 2025Topic: Chronic Heart FailureSession Title: Late Breaking Science in Heart Failure, Cardiomyopathies, Pulmonary Hypertension and Valvular Heart DiseaseSession Type: Late Breaking ScienceSession Time: 4:00 - 5:00 PM CESTPresentation Time: 4:20 PM CESTLocation: Room 1Title: SEQUOIA-HCM: Effect of Aficamten Treatment on Patients with Hypertrophic Obstructive Cardiomyopathy by Geographical RegionPresenter: Caroline Coats, M.D., Ph.D., Lead Clinician, West of Scotland Inherited Cardiac Conditions Service, Honorary Senior Lecturer, School of Cardiovascular and Metabolic Health, University of GlasgowDate: May 18, 2025Topic: Chronic Heart FailureSession Title: Hottest Trials and Trial Updates (2)Session Type: Late Breaking ScienceSession Time: 10:45 AM - 12:15 PM CESTPresentation Time: 11:11 AM CESTLocation: Room 1Title: The Effect of Omecamtiv Mecarbil on Outcomes Analyzed Using the Win Ratio: An Exploratory Analysis of GALACTIC-HFPresenter: Kieran F. Docherty, Ph.D., Clinical Senior Lecturer in Heart Failure and Clinical Trials and Honorary Consultant Cardiologist, University of GlasgowDate: May 19, 2025Topic: PharmacotherapySession Title: Clinical Trials Updates in Medical TherapySession Type: Late Breaking ScienceSession Time: 1:45 PM - 2:45 PM CESTPresentation Time: 2:25 PM CESTLocation: Room 1ePoster PresentationTitle: Associations Between Age and Sex and Cardiovascular Outcomes in Patients with Non-Obstructive Hypertrophic CardiomyopathyPresenter: Paulos Gebrehiwet, Ph.D., M.S., Senior Manager, Health Economics and Outcomes Research, CytokineticsDate: May 17, 2025Topic: ClinicalSession Title: ePosters in Myocardial Disease (2)Session Type: ePostersSession Time: 9:00 AM - 5:00 PM CESTPresentation Time: 1:26 PM CESTLocation: ePosters Screen 14 - Research GatewayAbout CytokineticsCytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.Forward-Looking StatementsThis press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements

GlobeNewswire
Apr 10th, 2025
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO

– Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA...

Here Novi
Mar 21st, 2025
Cytokinetics Launches EARTH-HCM for Hypertrophic Cardiomyopathy Awareness

Cytokinetics launches EARTH-HCM for hypertrophic cardiomyopathy awareness.

Investing.com
Mar 20th, 2025
Cytokinetics launches interactive HCM public health tool

Cytokinetics launches interactive HCM public health tool.

Recently Posted Jobs

Sign up to get curated job recommendations

Cytokinetics is Hiring for 7 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Cytokinetics's jobs every few hours, so check again soon! Browse all jobs →